Yang Hongqiong, Zhou Yaojun, Wang Liangzhi, Gu Tianyi, Lv Mengjia, Sun Jinling, Tu Chao, He Junbo
Department of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Department of Surgical Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Gastroenterol Res Pract. 2021 Feb 22;2021:8960315. doi: 10.1155/2021/8960315. eCollection 2021.
Five electronic databases were searched for eligible records. Outcomes were presented and analyzed according to the objective response rate (ORR), progression-free survival (PFS) rate, and overall survival (OS) rate. Five records involving 2,024 participants were included in the study. The pooled analysis of OS and PFS were longer with ramucirumab (RAM) therapy than without RAM for OS (odds ratio (OR) = 0.90, 95% confidence interval (CI) = 0.82-1.00, = 0.05) and PFS (OR = 0.74, 95%CI = 0.57-0.96, = 0.02). Moreover, compared with the current first-line chemotherapy, the OS (OR = 0.93, 95%CI = 0.83-1.04, = 0.19) and PFS (OR = 0.82, 95%CI = 0.64-1.06, = 0.13) results were not significantly higher with RAM. The ORRs of the patients in the RAM therapy groups were significantly higher than those in the groups without RAM (OR = 1.40, 95%CI = 1.14-1.73, = 0.001).
检索了五个电子数据库以获取符合条件的记录。根据客观缓解率（ORR）、无进展生存期（PFS）率和总生存期（OS）率呈现并分析结果。该研究纳入了五项涉及2024名参与者的记录。与未使用雷莫西尤单抗（RAM）治疗相比，使用RAM治疗的OS和PFS的汇总分析结果显示，OS（优势比（OR）=0.90，95%置信区间（CI）=0.82 - 1.00，P = 0.05）和PFS（OR = 0.74，95%CI = 0.57 - 0.96，P = 0.02）更长。此外，与当前的一线化疗相比，使用RAM治疗的OS（OR = 0.93，95%CI = 0.83 - 1.04，P = 0.19）和PFS（OR = 0.82，95%CI = 0.64 - 1.06，P = 0.13）结果并没有显著更高。RAM治疗组患者的ORR显著高于未使用RAM的组（OR = 1.40，95%CI = 1.14 - 1.73，P = 0.001）。
